Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.

Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO; ACTG A5353 Study Team .

J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564.

PMID:
30668695
2.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
3.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J.

J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7.

4.

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM.

Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.

5.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

6.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR.

Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.

PMID:
28750935
7.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team.

Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Erratum in: Lancet HIV. 2017 Dec;4(12 ):e535.

PMID:
28729158
8.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR.

Lancet HIV. 2017 Aug;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1. Epub 2017 May 22.

PMID:
28546090
9.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, Griffith SK, Clair MHS, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team.

Lancet Infect Dis. 2015 Oct;15(10):1145-1155. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19.

PMID:
26201299
10.

Regional variation in HIV clinical trials participation in the United States.

Heumann C, Cohn SE, Krishnan S, Castillo-Mancilla JR, Cespedes M, Floris-Moore M, Smith KY; ACTG Underrepresented Populations Survey Group.

South Med J. 2015 Feb;108(2):107-16. doi: 10.14423/SMJ.0000000000000234.

11.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD.

J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25.

12.

Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials.

Castillo-Mancilla JR, Cohn SE, Krishnan S, Cespedes M, Floris-Moore M, Schulte G, Pavlov G, Mildvan D, Smith KY; the ACTG Underrepresented Populations Survey Group.

HIV Clin Trials. 2014 Jan-Feb;15(1):14-26. doi: 10.1310/hct1501-14.

13.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

14.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM.

Clin Infect Dis. 2013 Dec;57(11):1607-17. doi: 10.1093/cid/cit595. Epub 2013 Sep 17.

15.

Addressing disparities in HIV mortality: antiretroviral therapy is necessary but not sufficient.

Smith KY.

Clin Infect Dis. 2013 Jun;56(12):1810-1. doi: 10.1093/cid/cit116. Epub 2013 Mar 1. No abstract available.

PMID:
23457075
16.

Racial/ethnic disparities in engagement in care and viral suppression in a large urban HIV clinic.

Adeyemi OM, Livak B, McLoyd P, Smith KY, French AL.

Clin Infect Dis. 2013 May;56(10):1512-4. doi: 10.1093/cid/cit063. Epub 2013 Feb 5. No abstract available.

17.

Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K.

J Natl Med Assoc. 2012 Jul-Aug;104(7-8):366-76.

PMID:
23092052
18.

Seroprevalence study using oral rapid HIV testing in a large urban emergency department.

Jain S, Lowman ES, Kessler A, Harper J, Rumoro DP, Smith KY, Purim-Shem-Tov Y, Kessler HA.

J Emerg Med. 2012 Nov;43(5):e269-75. doi: 10.1016/j.jemermed.2012.02.021. Epub 2012 Apr 26. Erratum in: J Emerg Med. 2013 Jun;44(6):1212.

PMID:
22541880
19.

Treating women with HIV: is it different than treating men?

Aziz M, Smith KY.

Curr HIV/AIDS Rep. 2012 Jun;9(2):171-8. doi: 10.1007/s11904-012-0116-x.

PMID:
22528764
20.

Community-associated methicillin-resistant Staphylococcus aureus colonization in high-risk groups of HIV-infected patients.

Popovich KJ, Smith KY, Khawcharoenporn T, Thurlow CJ, Lough J, Thomas G, Aroutcheva A, Zawitz C, Beavis KG, Weinstein RA, Hota B.

Clin Infect Dis. 2012 May;54(9):1296-303. doi: 10.1093/cid/cis030. Epub 2012 Feb 21.

21.

Challenges and successes in linking HIV-infected women to care in the United States.

Aziz M, Smith KY.

Clin Infect Dis. 2011 Jan 15;52 Suppl 2:S231-7. doi: 10.1093/cid/ciq047. Review.

PMID:
21342912
22.

Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):407-17. doi: 10.1089/aid.2009.0189.

23.

Effects of universal newborn hearing screening on an early intervention program for children with hearing loss, birth to 3 yr of age.

Halpin KS, Smith KY, Widen JE, Chertoff ME.

J Am Acad Audiol. 2010 Mar;21(3):169-75. doi: 10.3766/jaaa.21.3.5.

PMID:
20211121
24.

Paying the price for late starts and early stops: racial and sex disparities in HIV-related mortality.

Smith KY.

Clin Infect Dis. 2009 Nov 15;49(10):1579-81. doi: 10.1086/644773. No abstract available.

PMID:
19845470
25.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866
26.

Classic pyomyositis of the extremities as an unusual manifestation of Blastomyces dermatitidis: a report of two cases.

Lin MY, Chihara S, Smith KY, Kessler HA, Sha BE, Proia LA.

Mycoses. 2010 Jul;53(4):356-9. doi: 10.1111/j.1439-0507.2009.01714.x. Epub 2009 Jun 1. Review.

PMID:
19496934
27.

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

Smith KY, Weinberg WG, DeJesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; ALERT (COL103952) Study Team.

AIDS Res Ther. 2008 Mar 28;5:5. doi: 10.1186/1742-6405-5-5.

28.

Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138.

Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, Wang H, Sevin A, Tebas P, Sieg SF, Medvik K, Margolis DM, Pollard R, Ertl HC, Valdez H.

J Infect Dis. 2006 Dec 15;194(12):1677-85. Epub 2006 Nov 2.

PMID:
17109339
29.

Recognizing and managing common toxicities in patients receiving antiretroviral therapy.

Rawlings MK, Smith KY.

AIDS Read. 2004 Oct;14(10 Suppl):S12-5. Review.

PMID:
15497218
30.

Improving adherence to HAART.

Stone VE, Smith KY.

J Natl Med Assoc. 2004 Feb;96(2 Suppl):27S-29S. Review. No abstract available.

31.

Initiating antiretroviral therapy in asymptomatic HIV patients.

Smith KY, Virgil LA.

J Natl Med Assoc. 2004 Feb;96(2 Suppl):13S-16S. Review. No abstract available.

32.

Disparities and gaps in HIV research and care.

Smith KY, Orgain J, Scott R.

J Natl Med Assoc. 2004 Feb;96(2 Suppl):5S-7S. Review. No abstract available.

33.

Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.

Al-Harthi L, Voris J, Patterson BK, Becker S, Eron J, Smith KY, D'Amico R, Mildvan D, Snidow J, Pobiner B, Yau L, Landay A.

HIV Med. 2004 Jan;5(1):55-65.

34.

HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.

Tenorio AR, Smith KY, Kuritzkes DR, Sha BE, Donoval B, Young R, Jennings C, Bremer J, Shott S, Landay A, Kessler HA.

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):491-6.

PMID:
14657759
35.

Optimizing care for African-American HIV-positive patients.

Smith KY, Brutus A, Cathcart R, Gathe J Jr, Johnson W, Jordan W, Kwakwa HA, Nkwanyou J, Page C, Scott R, Vaughn AC, Virgil LA, Williamson D.

AIDS Patient Care STDS. 2003 Oct;17(10):527-38.

PMID:
14588093
36.

Protease inhibitor-sparing regimens.

Smith KY.

J Int Assoc Physicians AIDS Care (Chic). 2002 Oct-Dec;1(4):116-20. Review. No abstract available.

PMID:
12942669
37.

Role of Baseline pol Genotype in HIV-1 Fitness Evolution.

Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith KY, Colebunders RL, Landay A, Kuritzkes DR, Lederman MM, Vanham G, Quiñones-Mateu ME.

J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):448-60.

PMID:
12869833
38.

Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.

Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A; AIDS Clinical Trials Group Protocol 375 Team.

AIDS. 2002 Sep 27;16(14):1859-66.

PMID:
12351945
39.

CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART).

Smith KY, Kumar S, Pulvirenti JJ, Gianesin M, Kessler HA, Landay A.

J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):458-60. No abstract available.

PMID:
12138354
40.

Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy.

Talwani R, Falusi OM, Mendes de Leon CF, Nerad JL, Rich S, Proia LA, Sha BE, Smith KY, Kessler HA.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):191-5.

PMID:
12045682
41.
42.

Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens.

Smith KY, Steffens CM, Truckenbrod A, Landay A, Al-Harthi L.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):544-5. No abstract available.

PMID:
11981373
43.

A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia.

Keithley JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY.

Nutrition. 2002 Feb;18(2):201-4.

PMID:
11844656
44.

T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals.

Steffens CM, Smith KY, Landay A, Shott S, Truckenbrod A, Russert M, Al-Harthi L.

AIDS. 2001 Sep 28;15(14):1757-64.

PMID:
11579236
45.

Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.

Tenorio AR, Irlanda IE, Narkiewicz E, Smith KY, Kessler HA, Sha BE.

AIDS. 2000 Jul 7;14(10):1470-1. No abstract available.

PMID:
10930173
46.

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.

Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, Fox L, Spritzler J, Roe J, Lederman MB, Lederman HM, Evans TG, Heath-Chiozzi M, Lederman MM.

AIDS. 2000 Jan 7;14(1):11-21.

PMID:
10714563
47.

Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.

Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E, Kuritzkes D, Gross B, Francis I, McCune JM, Lederman MM.

J Infect Dis. 2000 Jan;181(1):141-7.

PMID:
10608760
48.

Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.

Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, Miyashiro D, Quinn JP, Weinstein RA, Trenholme GM.

J Infect Dis. 1996 Sep;174(3):529-36.

PMID:
8769610
49.

Fever of unknown origin in the elderly: lymphoma presenting as vertebral compression fractures.

Smith KY, Bradley SF, Kauffman CA.

J Am Geriatr Soc. 1994 Jan;42(1):88-92. No abstract available.

PMID:
8277122
50.

The leukemias. Definition, treatment, and nursing care.

Campbell JB, Preston R, Smith KY.

Nurs Clin North Am. 1983 Sep;18(3):523-41. Review.

PMID:
6351019

Supplemental Content

Loading ...
Support Center